ADOCIA Announces the Release of Its Universal Registration Document for the Year 2023

LYON, France--(BUSINESS WIRE)-- #BIOTECH--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today the filing of its 2023 Universal Registration Document with the “Autorité des marchés financiers” (AMF - the French financial markets regulator) on April 29, 2024. An electronic copy of this document is available o